German chemicals group Evonik Industries EVKn.DE said on Thursday its second-quarter core profit fell 38% from last year, although it came in at the upper end of its preliminary forecast range, as the economic environment remained difficult.
The company, whose products are used in goods from animal feed and diapers to Pfizer/BioNTech's COVID-19 vaccine, posted adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of 450 million euros ($494 million) for the quarter. This is above analysts' forecast of 447.6 million euros provided by Vara Research.
https://www.nasdaq.com/articles/evonik-posts-q2-core-profit-down-38
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.